Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer

Ni, Ling

doi:10.3389/fimmu.2022.887189

Cited by 9 publications

(2 citation statements)

References 84 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simultaneously, CIK cells enhance the antigen presentation specificity of DCs and the expression of co-stimulatory molecules, contributing to an overall increase in anti-tumor activity. Furthermore, co-culturing of DC and CIK cells inhibits the expression of human telomerase reverse transcriptase (hTERT) protein, curbing telomerase activity and impeding tumor cell proliferation 52 .…”

Section: Treat Cancer With Low-risk Immune Cell Therapiesmentioning

confidence: 99%

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

Han,

Zhang,

Zheng

et al. 2024

Cell Transplant

View full text Add to dashboard Cite

Immune cell therapy as a revolutionary treatment modality, significantly transformed cancer care. It is a specialized form of immunotherapy that utilizes living immune cells as therapeutic reagents for the treatment of cancer. Unlike traditional drugs, cell therapies are considered “living drugs,” and these products are currently customized and require advanced manufacturing techniques. Although chimeric antigen receptor (CAR)-T cell therapies have received tremendous attention in the industry regarding the treatment of hematologic malignancies, their effectiveness in treating solid tumors is often restricted, leading to the emergence of alternative immune cell therapies. Tumor-infiltrating lymphocytes (TIL) cell therapy, cytokine-induced killer (CIK) cell therapy, dendritic cell (DC) vaccines, and DC/CIK cell therapy are designed to use the body’s natural defense mechanisms to target and eliminate cancer cells, and usually have fewer side effects or risks. On the other hand, cell therapies, such as chimeric antigen receptor-T (CAR-T) cell, T cell receptor (TCR)-T, chimeric antigen receptor-natural killer (CAR-NK), or CAR-macrophages (CAR-M) typically utilize either autologous stem cells, allogeneic or xenogeneic cells, or genetically modified cells, which require higher levels of manipulation and are considered high risk. These high-risk cell therapies typically hold special characteristics in tumor targeting and signal transduction, triggering new anti-tumor immune responses. Recently, significant advances have been achieved in both basic and clinical researches on anti-tumor mechanisms, cell therapy product designs, and technological innovations. With swift technological integration and a high innovation landscape, key future development directions have emerged. To meet the demands of cell therapy technological advancements in treating cancer, we comprehensively and systematically investigate the technological innovation and clinical progress of immune cell therapies in this study. Based on the therapeutic mechanisms and methodological features of immune cell therapies, we analyzed the main technical advantages and clinical transformation risks associated with these therapies. We also analyzed and forecasted the application prospects, providing references for relevant enterprises with the necessary information to make informed decisions regarding their R&D direction selection.

show abstract

Section: Treat Cancer With Low-risk Immune Cell Therapiesmentioning

confidence: 99%

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

Han,

Zhang,

Zheng

et al. 2024

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Moreover, accumulating evidence indicated that tumor antigen–based DC vaccines exhibited effectiveness to induce the T-cell-mediated adaptive cytolytic immune responses in PC ( 46 ).The development of DCs vaccines aimed to connect the DCs with TAA to present the antigen and subsequently activate cytotoxic T cells. Currently, various types of DC-based vaccines were developed and in the clinical trial stage ( 47 ).…”

Section: Dendritic Cell Vaccines Of Pancreatic Cancermentioning

confidence: 99%

Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer

Zhang

Dai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The mutation of the crucial genes such as tumor suppressors or oncogenes plays an important role in the initiation and development of tumors. The non-synonymous mutations in the tumor cell genome will produce non-autologous proteins (neoantigen) to activate the immune system by activating CD4+ and CD8+ T cells. Neoantigen-based peptide vaccines have exhibited exciting therapeutic effects in treating various cancers alone or in combination with other therapeutic strategies. Furthermore, antigen-loaded DC vaccines are more powerful in inducing stronger immune responses than vaccines generated by antigens and adjuvants. Therefore, neoantigen-based dendritic cell (DC) vaccines could achieve promising effects in combating some malignant tumors. In this review, we summarized and discussed the recent research progresses of the neoantigen, neoantigen-based vaccines, and DC-based vaccine in pancreatic cancers (PCs). The combination of the neoantigen and DC-based vaccine in PC was also highlighted. Therefore, our work will provide more detailed evidence and novel opinions to promote the development of a personalized neoantigen-based DC vaccine for PC.

show abstract

Engineering Energy‐Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell‐Based Immunotherapy

Liu

Yan

Wen

et al. 2022

Advanced Therapeutics

View full text Add to dashboard Cite

Effective diagnosis and treatment of cancer is still a great challenge to modern medicine. The advent of immunotherapy is revolutionizing the field of cancer research while drug toxicity and low responsive rates have become the most serious concerns in current treatment regimes. Dendritic cells (DCs) are the strongest antigen-presenting immune cells and play an important role in the initiation and regulation of the immune response. They can engulf a variety of foreign substances, including cell lysates and nucleic acids, and present antigens to activate the immune system. Some nanomaterials in vitro activation systems for DCs provide new ideas for immune-related therapies for tumors. Among these, magnetic nanoparticles (MNPs) have gradually become a major focus of basic scientific research and clinical treatment due to their advantages of good biocompatibility, low toxic side effects, and high ability to respond to external stimulus. The emergence of MNPs provides a novel, safe, and effective way to enhance the anti-tumor immune response. In this review, the application of MNPs as platform materials combined with DC immunotherapy is discussed, with the intention of providing a reference for future disease immunotherapy.

show abstract

Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer

Cited by 9 publications

References 84 publications

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer

Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer

Engineering Energy‐Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell‐Based Immunotherapy

Contact Info

Product

Resources

About